Verastem Inc

verastem.com

What Do They Do?

Sells an oral package combining two cancer medicines in the United States for adults with recurrent low-grade serous ovarian cancer linked to a KRAS mutation, and develops other targeted cancer treatments.

How Do They Make Money?

Verastem sells its U.S. co-pack to specialty pharmacies and specialty distributors; sales count when the product is delivered, typically.

FY2025 revenue

Who Are Their Customers?

Verastem sells through specialty pharmacies and specialty distributors. Pharmacies dispense the medicine to patients; distributors resell it to health care organizations, while government agencies and private organizations may receive discounts or rebates.

Do Revenues Turn Into Profits?

No. It lost $209.5M in FY2025.

Operating income, FY2025

−550% of revenue

▲ +48% (Loss) vs FY2024 (−$115M, −1150%)

Net income, FY2025

−678% of revenue

▲ +60% (Loss) vs FY2024 (−$130.6M, −1306%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +1775%; vs $2.1M in Q2 FY2025
Net income: ▲ +34% (Loss); vs −$25.9M in Q2 FY2025

Growing. Revenue grew 15.1x in 4 years, from $2.1M in FY2021 to $30.9M in FY2025, about 97% a year.

From development to sales The older report described a company focused on developing cancer medicines; the latest report also describes U.S. sales of an approved combination medicine alongside its research pipeline.

Direct RAS targeting The older report emphasized RAF/MEK and FAK inhibitors; the latest report also describes direct targeting of RAS and development of inhibitors for a specific KRAS mutation.

Who Do They Compete With?

Competes with Abbvie, AstraZeneca, Bristol Myers Squibb, Erasca, Genentech, Novartis, Pfizer, Astellas Pharma, Bayer, BeOne, Boehringer Ingelheim, Chugai, D3 Bio, Eli Lilly, GenFleet, Incyte, Jacobio, Jiangsu Hengrui Pharmaceuticals, Quanta Therapeutics, and Ranok Therapeutics

Comments